Corcept (NASDAQ: CORT) executive reports stock grants and tax withholding moves

Rhea-AI Filing Summary

Corcept Therapeutics executive Sean Maduck reported equity award activity and related tax withholding. On March 2, 2026, he acquired two grants of common stock totaling 908 shares, including 454 purchase-plan shares priced under a company purchase plan and 454 shares granted at no cost as an award. On March 3, 2026, 110 shares were withheld by Corcept at a price of $35.97 per share to cover tax obligations tied to vesting restricted stock units, leaving 8,977 common shares held directly.

The filing also lists indirect ownership stakes through several entities, including the Sean and Molly Maduck Living Trust, MMM 2025, LLC, two SNM Grantor Retained Annuity Trusts, and Duckhill Capital, LLC. Maduck disclaims beneficial ownership of Duckhill Capital, LLC shares beyond his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maduck Sean

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		454(1)	A	$35.97(2)	8,633(3)	D
Common Stock	03/02/2026		A		454(4)	A	$0.00	9,087(3)	D
Common Stock	03/03/2026		F(5)		110	D	$35.97(6)	8,977(7)	D
Common Stock								5,147	I	See Footnote(8)
Common Stock								20,570	I	See Footnote(9)
Common Stock								40,000	I	See Footnote(10)
Common Stock								34,000	I	See Footnote(11)
Common Stock								10,000	I	See Footnote(12)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

6. The closing price on March 2, 2026 was used to calculate the withholding obligation.

7. Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

8. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

9. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.

10. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

11. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

12. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Sean Maduck report in Corcept Therapeutics (CORT) stock?

Sean Maduck reported equity awards and tax withholding in Corcept common stock. He received two stock grants totaling 908 shares on March 2, 2026, and 110 shares were withheld on March 3, 2026 to satisfy tax obligations tied to vesting restricted stock units.

Did the Corcept (CORT) Form 4 show an open-market stock sale by Sean Maduck?

The Form 4 does not show an open-market sale by Sean Maduck. Instead, 110 shares were withheld by Corcept at $35.97 per share to cover tax withholding on vesting restricted stock units, a common administrative disposition rather than a discretionary market sale.

How many Corcept (CORT) shares does Sean Maduck hold directly after these transactions?

After the reported transactions, Sean Maduck directly holds 8,977 shares of Corcept common stock. This reflects the net impact of his March 2, 2026 stock grants and the March 3, 2026 share withholding to satisfy associated tax obligations on vested restricted stock units.

What indirect Corcept (CORT) holdings related to Sean Maduck are disclosed?

The filing lists indirect holdings through the Sean and Molly Maduck Living Trust, MMM 2025, LLC, two SNM Grantor Retained Annuity Trusts, and Duckhill Capital, LLC. Maduck is trustee, member, manager, or president of these entities, and disclaims beneficial ownership in Duckhill Capital beyond any pecuniary interest.

What are the terms of Sean Maduck’s unvested Corcept (CORT) restricted stock awards?

Unvested awards include blocks of 266, 888, 228, and 205 shares granted in 2025, plus awards under the 2024 Purchase Plan. For each grant, 100% of the underlying shares vest on the one-year grant anniversary if he meets specified continued-service or ownership conditions.

How is the purchase price determined for Sean Maduck’s Corcept (CORT) purchase plan shares?

The purchase plan shares were bought under Corcept’s 2024 Incentive Award Plan. The price is set according to the purchase plan, using the closing market price of Corcept common stock on the day of purchase, such as the closing price on March 2, 2026.